Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mengpeng Li"'
Autor:
Xianjie Lu, Wei Wang, Yanming Liu, Na Song, Mengpeng Li, Xin Mu, Nan Zhang, Qingfa Chen, Licheng Jiang, Xianglin Kong, Peng Sun, Jiabei Tong, Yunping Zhang, Jingtao Li, Shengjun Ma, Fabin Han
Publikováno v:
Stem Cell Research, Vol 60, Iss , Pp 102685- (2022)
Mutations in VPS13 gene have been recently reported as a genetic cause of Parkinson's disease (PD). In this study, we isolated the skin fibroblasts from a PD patient harboring VPS13A gene mutation (c. 4282_4289delinsA) and reprogrammed the fibroblast
Externí odkaz:
https://doaj.org/article/332c6bbf1a8544b9ba4ce0df5431b835
Autor:
Na Song, Yan Wang, Liangxing Zhou, Junli Zhang, Fan Wu, Mengpeng Li, Wei Wang, Yanming Liu, Xianjie Lu, Qingfa Chen, Nan Zhang, Yongjian Yan, Fabin Han
Publikováno v:
Neurological Sciences. 44:905-912
Autor:
Liangxing, Zhou, Mengpeng, Li, Zhengbin, Chai, Junli, Zhang, Kuan, Cao, Lei, Deng, Yanming, Liu, Cun, Jiao, Gang-Ming, Zou, Jibiao, Wu, Fabin, Han
Publikováno v:
Oncology Reports. 49
Autor:
Jin Huang, Chuanfei Wei, Yanming Liu, Dong Han, Xiwen Geng, Chuanguo Liu, Mengpeng Li, Juanli Chen, Fabin Han
Publikováno v:
Brain Science Advances. 5:21-40
Alzheimer’s disease (AD) is the most prevalent age-related neurodegenerative disease which is mainly caused by aggregated protein plaques in degenerating neurons of the brain. These aggregated protein plaques are mainly consisting of amyloid β (A
Autor:
Jianxun Wang, Yinfeng Zhang, Peifeng Li, Mengpeng Li, Ningning Tang, Yanyan Yang, Tao Yu, Shaoyan Jiang, Murugavel Ponnusamy
Publikováno v:
Expert Opinion on Therapeutic Patents. 27:1021-1029
A number of miRNAs have been reported to be critically involved in the regulation of cardiovascular disease (CVDs). Therefore, the development of potent analogues/inhibitors for miRNAs have thus become a key focus in the present drug discovery. In th
Autor:
Yinfeng Zhang, Peifeng Li, Kun Wang, Hong Xu, Jianxun Wang, Tao Yu, Murugavel Ponnusamy, Yan Liu, Yanyan Yang, Mengpeng Li
Publikováno v:
Expert opinion on therapeutic patents. 27(4)
FGFR1 is a well known molecular target for anticancer therapy. Many studies have proved that the regulation of FGFR1 activity is a promising therapeutic approach to treat a series of cancers. Therefore, the development of potent inhibitors has conseq